Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-20

Last Posted Date: 2013-05-30

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT00004900

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2004-08-13

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003284

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-08-13

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00003294

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-08-11

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Target Recruit Count: 60

Registration Number: NCT00002619

Locations: 🇺🇸
Kaplan Cancer Center, New York, New York, United States

Carboplatin in Patients With Progressive Gliomas

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-08-11

Last Posted Date: 2009-10-14

Lead Sponsor: Duke University

Target Recruit Count: 25

Registration Number: NCT00002749

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇨🇦
Hopital Sainte Justine, Montreal, Quebec, Canada

Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2004-08-05

Last Posted Date: 2013-04-12

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 55

Registration Number: NCT00004186

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2004-08-05

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004096

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: Cetuximab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation therapy

First Posted Date: 2004-08-05

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 74

Registration Number: NCT00089297

S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-08-02

Last Posted Date: 2012-07-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 96

Registration Number: NCT00003158

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸
CCOP - Columbus, Columbus, Ohio, United States

and more 83 locations

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-08-02

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 300

Registration Number: NCT00003214

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Klinik Hirslanden, Zurich, Switzerland
🇨🇭
City Hospital Triemli, Zurich, Switzerland

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy